[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 27, 1963

Methotrexate in the treatment of cancer; report of the proceedings of a symposium at the Royal Society of Medicine, 18 September, 1961, sponsored by Lederle Laboratories, a Division of Cyanamid of Great Britain, Ltd

Author Affiliations

Jackson, Miss.

 

Edited by Ruth Porter and Eve Wiltshaw. 80 p. $7. Williams & Wilkins, 428 E Preston St, Baltimore 2, 1962

JAMA. 1963;185(4):336. doi:10.1001/jama.1963.03060040120055

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

This book is a composite of a group of papers presented at a symposium of the Royal Society of Medicine on Sept 18, 1961. It opens with a review of the biochemistry and pharmacology of methotrexate and the clinical significance of some recent work. This is followed by a section on the systemic use of the agent, both alone and in combination with other cancer chemotherapeutic agents; there are included sections on the infusion use of methotrexate and the intrathecal use in acute leukemia involving the central nervous system. The material presented is a very worthwhile addition to the library of those interested in cancer chemotherapy. In particular, the discussion section following each major group of papers is very worthwhile, as it presents the review of many experts in these fields. The papers are fully reproduced with colored or black-and-white photographs, as well as charts. This symposium adequately points out

First Page Preview View Large
First page PDF preview
First page PDF preview
×